{
    "clinical_study": {
        "@rank": "148131", 
        "arm_group": [
            {
                "arm_group_label": "Control ONS", 
                "arm_group_type": "Active Comparator", 
                "description": "ONS without AN777"
            }, 
            {
                "arm_group_label": "Investigational ONS", 
                "arm_group_type": "Experimental", 
                "description": "ONS containing AN777"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will evaluate the effects of oral nutritional supplements (ONS) on attenuating the\n      lean body mass (LBM) loss that occurs after bed rest."
        }, 
        "brief_title": "Evaluation of an Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects.", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u2265 60 to \u2264 79 years\n\n          2. Body Mass Index (BMI) >20 but \u2264 35 kg/m2.\n\n          3. Short Physical Performance Battery (SPPB) score of > 9 (fully functional with no\n             mobility limitations).\n\n          4. Triacylglyceride (TAG) level is \u2264  250 mg/dl and LDL cholesterol is \u2264 150 mg/dl.\n\n          5. Compliance with the various activity levels required for this study.\n\n          6. Ankle brachial index within the normal range, between 1 and 1.4.\n\n          7. Physical activity score within the 2008 Guidelines for Americans.\n\n          8. Normal-good handgrip strength.\n\n        Exclusion Criteria:\n\n          1. Type I or Type II Diabetes Mellitus.\n\n          2. Abnormal fasting blood glucose level.\n\n          3. Major surgery, less than 6 weeks prior to enrollment in the study, or subject has\n             planned elective surgery requiring 2 or more days of hospitalization.\n\n          4. History of pressure ulcers.\n\n          5. Stated history of Deep Vein Thrombosis (DVT), recent pulmonary embolism, carotid\n             atherosclerosis, transient ischemic attack (TIA), or has a positive D-dimer test and\n             lower extremity ultrasound at screening, or a known hypercoaguable condition, or\n             other clotting or bleeding disorders, or is currently prescribed blood thinners.\n\n          6. Varicose veins that would result in significant discomfort while wearing TED hose\n             and/or SCD.\n\n          7. Stated autoimmune disease or active malignant disease.\n\n          8. Estimated glomerular filtration rate is < 60ml/min/1.73m2.\n\n          9. Current significantly impaired liver function or hepatic enzyme tests are \u22652.5 times\n             normal limit.\n\n         10. Significant cardiovascular event \u2264 6 months prior to screening visit; or stated\n             history of congestive heart failure; or subject has evidence of cardiovascular\n             disease assessed during the electrocardiogram (EKG) at screening.\n\n         11. Hypo- or hyper-thyroidism, or other endocrinopathies associated with excessive\n             androgen secretion.\n\n         12. Refractory anemia with hemoglobin value <11.0 g/dl.\n\n         13. Chronic, contagious, infectious disease, such as active tuberculosis, hepatitis B or\n             C, or HIV.\n\n         14. Current infection (requiring prescription antimicrobial or antiviral medication, or\n             hospitalization), or has received corticosteroid treatment (with the exception of\n             inhaled or topical steroids) in the last 3 months.\n\n         15. Currently being prescribed or has taken prescribed (high dose), but not over the\n             counter, anti-inflammatory medication in the 6 weeks prior to screening.\n\n         16. History of allergy to any of the ingredients in the study products.\n\n         17. Currently taking statins and has a stated history of statin induced myopathy.\n\n         18. Obstruction of the gastrointestinal tract precluding ingestion of the study product,\n             inflammatory bowel disease, short bowel syndrome or other severe forms of\n             gastrointestinal disease.\n\n         19. Stated uncontrolled severe diarrhea, nausea or vomiting.\n\n         20. Amputee.\n\n         21. Actively pursuing weight loss or gain.\n\n         22. Cannot refrain from taking medications/dietary supplements (all forms)/substances\n             that could modulate metabolism or body weight.\n\n         23. Cannot refrain from taking prescription level doses of eicosapentaenoic acid (EPA) \u00b1\n             docosahexaenoic acid (DHA) (\u22651g/d), or vitamin D, (>1,000IU/d) during the study.\n\n         24. Cannot refrain from smoking or discontinue the use of nicotine (all forms including\n             patches) or tobacco during the study.\n\n         25. One or more metal implants.\n\n         26. Currently diagnosis or a history of severe dementia or delirium, eating disorder,\n             history of significant neurological or psychiatric disorder, alcoholism, substance\n             abuse or other conditions that may interfere with study product consumption or\n             compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "79 Years", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "76", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02090387", 
            "org_study_id": "BL20"
        }, 
        "intervention": [
            {
                "arm_group_label": "Control ONS", 
                "description": "2 servings a day", 
                "intervention_name": "ONS without AN777", 
                "intervention_type": "Other", 
                "other_name": "Commercially available ONS"
            }, 
            {
                "arm_group_label": "Investigational ONS", 
                "description": "2 servings a day", 
                "intervention_name": "ONS containing AN777", 
                "intervention_type": "Other", 
                "other_name": "Investigational ONS"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72205-7199"
                    }, 
                    "name": "University of Arkansas for Medical Sciences (UAMS)"
                }, 
                "investigator": {
                    "last_name": "Robert Wolfe, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32804"
                    }, 
                    "name": "Florida Hospital Translational Research Institute for Metabolism and Diabetes"
                }, 
                "investigator": {
                    "last_name": "Bret Goodpaster, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "College Station", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77843-4253"
                    }, 
                    "name": "Center of Translational Research in Aging & Longevity"
                }, 
                "investigator": {
                    "last_name": "Nicolaas EP Deutz, PhD, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of a Complete Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects During Bed Rest and Recovery.", 
        "overall_contact": {
            "email": "kristen.deluca@abbott.com", 
            "last_name": "Kristen DeLuca, MS, RD", 
            "phone": "614-624-5455"
        }, 
        "overall_official": {
            "affiliation": "Abbott Nutrition", 
            "last_name": "Owen Kelly, Ph.D", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline", 
            "measure": "Total lean body mass", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Study Day 10"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02090387"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline", 
                "measure": "Hand-grip strength", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Study Day 10, Study Week 6 and 12"
            }, 
            {
                "description": "Change from baseline", 
                "measure": "Short Physical Performance Battery (SPPB)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Study Day 10, Study Week 6 and 12"
            }, 
            {
                "description": "Change from baseline", 
                "measure": "Isokinetic leg strength", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Study Day 10 and Study Week 12"
            }, 
            {
                "description": "Calculated BMI = weight/height2 (kg/m2).", 
                "measure": "Body Mass Index (BMI)", 
                "safety_issue": "No", 
                "time_frame": "Screening Visits 1 and 3; Baseline; Study Days 2, 4, 6, 8 and 10; Study Weeks 3, 6, 9 and 12"
            }, 
            {
                "description": "Measured by DXA; Change from baseline", 
                "measure": "Lower extremity lean mass", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Study Day 10, Study Weeks 6 and 12"
            }
        ], 
        "source": "Abbott Nutrition", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abbott Nutrition", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}